Arvinas, Inc. (NASDAQ:ARVN) Receives $56.08 Average PT from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received a consensus rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $37.47.

ARVN has been the subject of a number of recent analyst reports. Citigroup cut their price target on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $81.00 target price on shares of Arvinas in a report on Tuesday, March 11th. The Goldman Sachs Group downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and dropped their target price for the company from $70.00 to $15.00 in a report on Thursday, March 13th. Bank of America decreased their price target on shares of Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. Finally, Wells Fargo & Company set a $26.00 price target on shares of Arvinas and gave the company an “overweight” rating in a research report on Wednesday, March 12th.

Insider Buying and Selling at Arvinas

In other news, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARVN. GF Fund Management CO. LTD. acquired a new position in Arvinas during the fourth quarter worth about $28,000. KBC Group NV lifted its holdings in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP lifted its holdings in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Arvinas in the fourth quarter valued at about $171,000. Finally, Tema Etfs LLC purchased a new stake in shares of Arvinas in the fourth quarter valued at about $227,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Price Performance

ARVN opened at $8.42 on Wednesday. The company’s 50 day simple moving average is $16.87 and its two-hundred day simple moving average is $21.59. Arvinas has a 1-year low of $7.91 and a 1-year high of $44.85. The firm has a market capitalization of $579.06 million, a price-to-earnings ratio of -3.04 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the business posted ($2.53) EPS. On average, equities analysts anticipate that Arvinas will post -3.81 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.